Finger-Prick blood tests could let lung cancer patients skip clinic visits
NCT ID NCT07823725
First seen Sep 16, 2026 · Last updated Sep 21, 2026 · Updated 2 times
Summary
Researchers are testing whether people with non-small cell lung cancer can collect their own small blood samples at home using a finger-prick kit. Participants receive standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib, and the samples measure how much cancer medicine is in their blood. The study checks how easy the sampling is to use, whether the samples are suitable for lab analysis, and how patients and healthcare professionals experience this approach. About 80 participants will take part and be followed for roughly 3 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a finger-prick capillary blood self-sampling kit for measuring cancer drug levels at home
- What this could lead to
- If it works, people with lung cancer could one day monitor their drug levels from home instead of traveling to a clinic for blood draws.
- What could go wrong
- This is a small feasibility study, so it may show that home sampling is too hard for some patients or that samples are not reliable enough for lab analysis. The drug-level results will not be used to change anyone's treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Age ≥18 years. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC). Receiving ongoing standard-of-care treatment with docetaxel, paclitaxel, alectinib, or lorlatinib. Able to understand Swedish or English and provide written informed consent. Willing and able to comply with study-required procedures, including blood sample collection. Able to perform capillary self-sampling at home, with or without support from a caregiver or healthcare professional. Access to a stable home or remote environment suitable for sample collection and, where applicable, home nurse visits. Able to participate in the required sample collection and shipping procedures, independently or with support from a family member or caregiver. Exclusion Criteria: Concurrent participation in another interventional study that may affect pharmacokinetics. Severe coagulopathy or another contraindication to capillary blood sampling. Known hypersensitivity to a previously used adhesion system used for sample collection. Any condition that, in the investigator's judgment, would make study participation unsafe or infeasible, including skin infection or another skin condition at the intended sample collection site.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (mesh term: carcinoma, non-small-cell lung) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institution of Oncology-Pathology
Stockholm, 17166, Sweden
-
Karolinska Univeristy Hospital, Theme Cancer, Lung Cancer Department
Stockholm, 17176, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.